<p>根据其最近向证券交易委员会提交的 13F 文件，MPM Bioimpact LLC 在第四季度购买了 Veru Inc.（NASDAQ:VERU - 免费报告）的新股份。该公司购买了 4,285,365 股，价值约为 2,788,000 美元。到最近一个季度末，MPM Bioimpact LLC 持有 Veru 约 2.93% 的股份。</p>
<p>其他一些对冲基金和机构投资者最近也调整了他们对 VERU 的持股。Cetera Investment Advisers 在第四季度将其在 Veru 的持股增加了 26.1%。Cetera Investment Advisers 现在拥有 95,210 股该公司的股票，价值 62,000 美元，此前在上个季度购买了额外的 19,724 股。美国银行（Bank of America Corp DE）在第四季度将其在 Veru 的持股增加了 17.5%。美国银行现在拥有 217,792 股该公司的股票，价值 142,000 美元，此前在此期间购买了额外的 32,447 股。Jane Street Group LLC 在第四季度将其在 Veru 的持股增加了 35.2%。Jane Street Group LLC 现在拥有 130,406 股该公司的股票，价值 85,000 美元，此前在此期间获得了额外的 33,952 股。Integrated Wealth Concepts LLC 在第四季度将其在 Veru 的持股增加了 31.3%。Integrated Wealth Concepts LLC 现在拥有 85,900 股该公司的股票，价值 56,000 美元，此前在上个季度购买了额外的 20,500 股。最后，NewEdge Advisors LLC 在第四季度将其在 Veru 的持股增加了 2,500.0%。NewEdge Advisors LLC 现在拥有 130,000 股该公司的股票，价值 85,000 美元，此前在此期间购买了额外的 125,000 股。机构投资者持有该公司 47.16% 的股份。</p>
<h2>Veru 股票表现</h2>
<p>NASDAQ:VERU 周三开盘价为 0.52 美元。Veru Inc.的 52 周低点为 0.45 美元，52 周高点为 1.57 美元。该公司的市值为 7548 万美元，市盈率为-1.98，贝塔值为-0.74。该股票的 50 日移动平均线为 0.53 美元，200 日移动平均线为 0.63 美元。</p>
<p>Veru（NASDAQ:VERU - 获取免费报告）最近于 5 月 8 日（星期四）发布了其财报。该公司报告本季度每股收益为（0.05）美元，超出分析师一致预期的（0.06）美元，超出幅度为 0.01 美元。Veru 的股本回报率为-112.75%，净利润率为-223.85%。股票分析师预测 Veru Inc.在当前财政年度的每股收益将为-0.22 美元。</p>
<h2>Veru 内部交易</h2>
<p>在其他 Veru 新闻中，董事 Michael L. Rankowitz 于 2 月 18 日（星期二）购买了 95,279 股该股票。该股票的平均购买成本为每股 0.55 美元，总价值为 52,403.45 美元。收购后，该董事现在持有 195,279 股该公司的股票，价值约为 107,403.45 美元。这笔交易代表了他们持股的 95.28% 的增长。该购买在向证券交易委员会提交的文件中披露，文件可通过此链接获取。公司内部人士持有该公司 14.90% 的股份。</p>
<h2>Veru 简介</h2>
<p>（免费报告）</p>
<p>Veru Inc.是一家处于临床后期的生物制药公司，专注于开发治疗代谢疾病、肿瘤学和急性呼吸窘迫综合症（ARDS）的药物。其市场产品包括 FC2 女性避孕套，用于防止意外怀孕和传播性传播感染的双重保护。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Veru</li>
<li>高股息 REIT：它们是理想的多元化方式吗？</li>
<li>制药火售：3 只 RSI 认为你不应忽视的股票</li>
<li>什么是财报？</li>
<li>AppLovin 因财报激增：这家科技公司接下来会怎样？</li>
<li>宝洁公司（Procter &amp; Gamble NYSE: PG）在不稳定的指引后回落</li>
<li>美国监管机构针对 CrowdStrike：这是信号还是噪音？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSVQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSVQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Veru 吗？</h2>
<p>在你考虑 Veru 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Veru 并不在名单上。</p>
<p>虽然 Veru 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERU

<p>MPM Bioimpact LLC 在第四季度收购了 4,285,365 股 Veru Inc.（纳斯达克代码：VERU），价值约 279 万美元，占公司约 2.93% 的股份。其他机构投资者也增加了对 Veru 的持股。该股票开盘价为 0.52 美元，52 周价格区间为 0.45 至 1.57 美元。Veru 报告的季度每股亏损为 0.05 美元，超出预期，分析师预测本财年将亏损 0.22 美元。内部人士持有 14.90% 的股份，公司专注于开发代谢疾病和肿瘤学的治疗方案</p>

<p>MPM Bioimpact LLC purchased a new stake in Veru Inc. (NASDAQ:VERU - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,285,365 shares of the company's stock, valued at approximately $2,788,000. MPM Bioimpact LLC owned approximately 2.93% of Veru at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据其最近向证券交易委员会提交的 13F 文件，MPM Bioimpact LLC 在第四季度购买了 Veru Inc.（NASDAQ:VERU - 免费报告）的新股份。该公司购买了 4,285,365 股，价值约为 2,788,000 美元。到最近一个季度末，MPM Bioimpact LLC 持有 Veru 约 2.93% 的股份。</p>
</div><p>A number of other hedge funds and other institutional investors have also recently modified their holdings of VERU. Cetera Investment Advisers raised its holdings in Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after purchasing an additional 19,724 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Veru by 17.5% in the 4th quarter. Bank of America Corp DE now owns 217,792 shares of the company's stock worth $142,000 after purchasing an additional 32,447 shares during the period. Jane Street Group LLC grew its stake in shares of Veru by 35.2% during the 4th quarter. Jane Street Group LLC now owns 130,406 shares of the company's stock worth $85,000 after acquiring an additional 33,952 shares during the period. Integrated Wealth Concepts LLC grew its stake in Veru by 31.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock valued at $56,000 after buying an additional 20,500 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Veru by 2,500.0% during the 4th quarter. NewEdge Advisors LLC now owns 130,000 shares of the company's stock valued at $85,000 after purchasing an additional 125,000 shares during the period. Institutional investors own 47.16% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也调整了他们对 VERU 的持股。Cetera Investment Advisers 在第四季度将其在 Veru 的持股增加了 26.1%。Cetera Investment Advisers 现在拥有 95,210 股该公司的股票，价值 62,000 美元，此前在上个季度购买了额外的 19,724 股。美国银行（Bank of America Corp DE）在第四季度将其在 Veru 的持股增加了 17.5%。美国银行现在拥有 217,792 股该公司的股票，价值 142,000 美元，此前在此期间购买了额外的 32,447 股。Jane Street Group LLC 在第四季度将其在 Veru 的持股增加了 35.2%。Jane Street Group LLC 现在拥有 130,406 股该公司的股票，价值 85,000 美元，此前在此期间获得了额外的 33,952 股。Integrated Wealth Concepts LLC 在第四季度将其在 Veru 的持股增加了 31.3%。Integrated Wealth Concepts LLC 现在拥有 85,900 股该公司的股票，价值 56,000 美元，此前在上个季度购买了额外的 20,500 股。最后，NewEdge Advisors LLC 在第四季度将其在 Veru 的持股增加了 2,500.0%。NewEdge Advisors LLC 现在拥有 130,000 股该公司的股票，价值 85,000 美元，此前在此期间购买了额外的 125,000 股。机构投资者持有该公司 47.16% 的股份。</p>
</div><h2>Veru Stock Performance</h2>
<div class="lb-trans"><h2>Veru 股票表现</h2>
</div><p>NASDAQ:VERU opened at $0.52 on Wednesday. Veru Inc. has a 52-week low of $0.45 and a 52-week high of $1.57. The firm has a market capitalization of $75.48 million, a price-to-earnings ratio of -1.98 and a beta of -0.74. The stock has a fifty day moving average of $0.53 and a 200 day moving average of $0.63.</p>
<div class="lb-trans"><p>NASDAQ:VERU 周三开盘价为 0.52 美元。Veru Inc.的 52 周低点为 0.45 美元，52 周高点为 1.57 美元。该公司的市值为 7548 万美元，市盈率为-1.98，贝塔值为-0.74。该股票的 50 日移动平均线为 0.53 美元，200 日移动平均线为 0.63 美元。</p>
</div><p>Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. Equities analysts forecast that Veru Inc. will post -0.22 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Veru（NASDAQ:VERU - 获取免费报告）最近于 5 月 8 日（星期四）发布了其财报。该公司报告本季度每股收益为（0.05）美元，超出分析师一致预期的（0.06）美元，超出幅度为 0.01 美元。Veru 的股本回报率为-112.75%，净利润率为-223.85%。股票分析师预测 Veru Inc.在当前财政年度的每股收益将为-0.22 美元。</p>
</div><h2>Insider Transactions at Veru</h2>
<div class="lb-trans"><h2>Veru 内部交易</h2>
</div><p>In other Veru news, Director Michael L. Rankowitz purchased 95,279 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $0.55 per share, with a total value of $52,403.45. Following the acquisition, the director now owns 195,279 shares in the company, valued at approximately $107,403.45. This trade represents a 95.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Company insiders own 14.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Veru 新闻中，董事 Michael L. Rankowitz 于 2 月 18 日（星期二）购买了 95,279 股该股票。该股票的平均购买成本为每股 0.55 美元，总价值为 52,403.45 美元。收购后，该董事现在持有 195,279 股该公司的股票，价值约为 107,403.45 美元。这笔交易代表了他们持股的 95.28% 的增长。该购买在向证券交易委员会提交的文件中披露，文件可通过此链接获取。公司内部人士持有该公司 14.90% 的股份。</p>
</div><h2>Veru Profile</h2>
<div class="lb-trans"><h2>Veru 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.</p>
<div class="lb-trans"><p>Veru Inc.是一家处于临床后期的生物制药公司，专注于开发治疗代谢疾病、肿瘤学和急性呼吸窘迫综合症（ARDS）的药物。其市场产品包括 FC2 女性避孕套，用于防止意外怀孕和传播性传播感染的双重保护。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Veru</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
<li>What Are Earnings Reports?</li>
<li>AppLovin Surges on Earnings: What's Next for This Tech Standout?</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Veru</li>
<li>高股息 REIT：它们是理想的多元化方式吗？</li>
<li>制药火售：3 只 RSI 认为你不应忽视的股票</li>
<li>什么是财报？</li>
<li>AppLovin 因财报激增：这家科技公司接下来会怎样？</li>
<li>宝洁公司（Procter &amp; Gamble NYSE: PG）在不稳定的指引后回落</li>
<li>美国监管机构针对 CrowdStrike：这是信号还是噪音？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSVQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VERU"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Veru Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Veru 吗？</h2>
</div><p>Before you consider Veru, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Veru 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Veru 并不在名单上。</p>
</div><p>While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Veru 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MPM Bioimpact LLC 收购了 Veru Inc.（NASDAQ:VERU）的 4,285,365 股股票